Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice: Laboratory investigation

Journal of Neurosurgery

Volumn 113, Issue 2, 2010, Pages 270-279

  Saka, Makoto ^a   Amano, Takayuki ^a   Kajiwara, Koji ^a   Yoshikawa, Koichi ^a   Ideguchi, Makoto ^a   Nomura, Sadahiro ^a   Fujisawa, Hirosuke ^a   Kato, Shoichi ^a   Fujii, Masami ^a   Ueno, Koji ^a   Hinoda, Yuji ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cell; Il13ra2; Malignant glioma; Mouse; mRNA; Vaccination therapy

Indexed keywords

CELL PROTEIN; DENDRITIC CELL VACCINE; INTERLEUKIN 13 RECEPTOR ALPHA2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DENDRITIC CELL; ENDOSOME; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GLIOMA; HISTOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYSOSOME; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN TRANSPORT; SURVIVAL RATE; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; BONE MARROW CELLS; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CHLOROQUINE; DENDRITIC CELLS; GENE THERAPY; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOPHENOTYPING; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PLASMIDS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSFECTION;

EID: 77955609177     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.9.JNS09708     Document Type: Article

References (60)

1. Amano T, Kajiwara K, Yoshikawa K, Morioka J, Nomura S, Fujisawa H, et al: Anti-tumor effects of vaccination with dendritic cells transfected with modified RHAMM (receptor for hyaluronan-mediated motility) mRNA for mice glioma. J Neurosurg 106:638-645, 2007
2. Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, et al: Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50:463-468, 2001
3. Arima K, Sato K, Tanaka G, Kanaji S, Terada T, Honjo E, et al: Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem 280:24915-24922, 2005
4. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177-1182, 1997
5. Babon A, Almunia C, Boccaccio C, Beaumelle B, Gelb MH, Menez A, et al: Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector. FEBS Lett 579:1658-1664, 2005
6. Cao H, Agrawal D, Kushner N, Touzjian N, Essex M, Lu Y: Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J Infect Dis 185:244-251, 2002
7. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL, et al: Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 54:372-382, 2005
8. Debinski W, Gibo DM: Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6:440-449, 2000
9. Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY: Receptor for interleukin 13 is abundantly and specifically overexpressed in patients with glioblastoma multiforme. Int J Oncol 15:481-486, 1999
10. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, et al: The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161:2317-2324, 1998
11. Eguchi J, Hatono M, Nishimura F: Identification of interleukin-13 receptor A2 peptide analogues capable of inducing improved antiglioma CTL response. Cancer Res 66:5883-5891, 2006
12. Ehtesham M, Kabos P, Gutierrez MAR, Samoto K, Black KL, Yu JS: Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 26:107-116, 2003
13. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A: IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12:99-106, 2006
14. Frauwirth K, Shastri N: Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathways. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains. Immunology 102:405-415, 2001
15. + T cells. Cancer Immunol Immunother 55:538-546, 2006
16. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al: IL13RA gene polymorphisms are associated with systemic sclerosis. J Rheumatol 33:2015-2019, 2006
17. Granel B, Chevillard C, Dessein A: Interleukin 13 and interleukin 13 receptor involvement in systemic sclerosis. Rev Med Interne 28:613-622, 2007
18. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, et al: Dendritic cells pulsed with tumor-specific peptide induce long lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50:158-166, 2002
19. Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 111:677-690, 2003
20. Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW: Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 31:528-533, 1992
21. Husain SR, Uri RK: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65:37-48, 2003
22. Insug O, Ku G, Ertl HCJ, Blanszczyk-Thurin M: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613-622, 2002
23. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK: Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implication for targeted therapies. Cancer Res 67:7983-7986, 2007
24. Jiang X, Lu X, Liu R, Zhang F, Zhao H: Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor alpha 2 peptide in vitro. Acta Biochim Biophys Sin (Shanghai) 39: 641-648, 2007
25. Joshi BH, Plautz GE, Puri RK: Interleukin-1 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60: 1168-1172, 2000
26. Kawakami M, Kawakami K, Takahashi S: Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101:1036-1042, 2004
27. Kerblat I, Tongiani-Dahshan S, Aude-Garcia C, Villiers M, Drouet C, Marche PN: Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized CD8+ or CD4+ T lymphocytes. Immunology 100:178-184, 2000
28. Kleihues P, Cavenee WK: World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of the Nervous System, ed 2. Albany: WHO Publications Centre USA, 2000
29. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001
30. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ: Rapid effector function in CD8+ memory T cells. J Exp Med 186:859-865, 1997
31. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al: Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurg Focus 9(6):e8, 2000
32. Melief CJ, Kast WM: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167-177, 1995
33. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W: IL-13a2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4:388-399, 2002
34. Morioka J, Kajiwara K, Yoshikawa K, Ideguchi M, Uchida T, Ohmoto Y, et al: Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effect in a murine brain tumor. J Neurooncol 60:13-23, 2002
35. Neild A, Murata T, Roy CR: Processing and major histocompatibility complex class II presentation of Legionella pneumophila antigens by infected macrophages. Infect Immun 73:2336-2343, 2005
36. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et al: The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65:191-199, 2008 (Pubitemid 351200461)
37. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al: Induction of tumor cell apoptosis in vivo increases tumor Antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905-4913, 2003
38. Ohkuma S, Poole B: Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75:3327-3331, 1978
39. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, et al: Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196-201, 1998
40. Orange DE, Jegathesan M, Blachere NE, Frank MO, Scher HI, Albert ML, et al: Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer Prostatic Dis 7:63-72, 2004
41. Parajuli P, Sloan AE: Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22:405-416, 2004
42. Parry RG, Gillespie KM, Mathieson PW: Effects of type 2 cytokines on glomerular epithelial cells. Exp Nephrol 9:275-283, 2001
43. Ponsaerts P, van Tendeloo VF, Berneman ZN: Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 134:378-384, 2003
44. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T: Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26:109-113, 2000
45. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, et al: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288, 2002
46. Schultz KR, Gilman AL: The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leuk Lymphoma 24:201-210, 1997
47. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55, 1998
48. Stewart LA: Chemotherapy in adult high-grade glioma. Lancet 359:1011-1018, 2002
49. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al: Promising survival for patient with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
50. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
51. Takagi Y, Kikuchi T, Niimura M, Ohno T: Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res 23:2553-2558, 2003
52. Van Meir EG, Bellail A, Phuphanich S: Emerging molecular therapies for brain tumors. Semin Oncol 31:38-46, 2004
53. Walker PR, Calzascia T, De Tribolet N, Dietrich PY: T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42:97-122, 2003
54. Wen PY, Kesari S: Malignant gliomas. Curr Neurol Neurosci Rep 4:218-227, 2004
55. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63:7462-7467, 2003
56. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, et al: Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11:5900-5911, 2005
57. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, et al: Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 62:2583-2591, 2002
58. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004
59. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001
60. Zheng W, Zhang J, Li J: The relation between IL-13Ra2 and prognosis in astrocytoma. Chin J Neurosurg 22:324, 2006